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any consensus is available about the system to avoid AK. The HAK appeared
when the liver is in its final position as demonstrated by our HAF measures
(HAF drop-down in all patients). The surgicel or the omentum interposition
guarantee a maintenance of a good HAF also when the abdominal wall closure
is performed.
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Background: Hepatic arterial complication after liver transplantation (LTx) is
a major source of morbidity and mortality. Only early diagnosis and treatment
will save the patient’s life. We analyzed consecutive more than 500 living donor
liver transplantation (LDLT) patients for risk factor and result.
Method: From August 2004 to May 2010, total 522 patients including pediatric
and adult LDLT were done by our center and retrospectively reviewed. Hepatic
arterial anastomosis was done under Microscope and by interrupted suture
with Prolene 8-0. We routinely checked intraoperative Doppler at POD#1, #3,
#5 or #7. Hepatic arterial complication included thrombosis and stricture.
Results: The overall complication rate related to arterial reconstruction in
LDLT was 4.6% (24 cases). 17 patients had an arterial stricture and 7 pa-
tients had an arterial thrombosis. 7 patients of 24 patients were explored and
revised hepatic artery. 2 of them underwent retransplantation because of re-
current thrombosis and hepatic failure. Another 6 patients were treated with in-
terventions. The rest 10 patients were only observed closely under antiplatelet
agents because of mild disease severity. Among 24 patients, 7 patients were
died. Only preoperative alcohol ingestion (p=0.014) and POD#7 Doppler RI in-
dex below 0.6 (p=0.039) were associated hepatic arterial complication. Against
noted risk factors of hepatic arterial complication, our analysis reveals that ar-
terial complication is not associated with arterial number, anatomy and pedi-
atric LTx. Most of the hepatic arterial complications (19 of 24 cases) occurred
within 1 month after LTx.
Conclusions: The risk factors of hepatic arterial complication after LDLT were
preoperative alcohol ingestion and POD#7 Doppler finding and most compli-
cations occurred within 1 month. Regular Doppler check after LDLT should be
considered as early diagnosis method for arterial complication and treatment
of hepatic arterial complication should be designed by individually.
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Organ shortage has been the ongoing obstacle to expand liver transplantation
world-wide.Living donor liver transplantation (LDLT) was hoped to improve this
shortage. We aimed to analyse the results of the evaluation of potential living
donors at our center and determine the prevalence of macrosteatosis.
Methods: From 2001 to 2010, 192 deceased donor liver transplants and 90 liv-
ing donors liver transplants (LDLT) were performed. 975 potential living donors
were worked up according to a step-wise evaluation protocol. Their age ranged
from 18 to 60 years, with 75% in the third and forth decades. They were all first
and second degree relatives of the patients.
Results: Only 90 (9.2%) were accepted for donation and 885 (90.8%) were
rejected. 793 (around 80%) were excluded at the earlier stages of evaluation:
either at initial screening due to high body mass index or due to incompatible
blood group, positive hepatitis serology, elevated liver enzymes, miscellaneous
systemic diseases, socioeconomic reasons, abnormal anatomy or insufficient
volume as determined by CT volumetry. 182 reached the step of liver biopsy.
Of these, 44 (24%) were rejected due to abnormal fat content. As regards the
remaining 138, 48 were excluded either due to abnormal histopathology (other
than steatosis) or the operation was aborted due to the recipients’ condition.
Finally 90 underwent donation.
Conclusion: There is no doubt that LDLT has helped in alleviating the severe
shortage of deceased organs in Saudi Arabia. However suitable living donors
are not easy to find especially right lobe donors. Our initial evaluation is ef-
fective in eliminating a large number of unsuitable donors.However,steatosis
remains a problem encountered at a later stage of the evaluation. The donor
evaluation process indeed remains to be a large burden on the resources of
our program
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Background: The development of Adult Living Donor Liver Transplantation
(ALDLTx) programs in many western LTx centers has decreased due to re-
ported donor morbidity/mortality.
Methods: The Belgian Royal Academy of Medicine proposed a national survey
in order to assess donor morbidity/mortality after ALDLTx in Belgium. Between
09/1999 & 09/2010, 143 ALDLTx were performed in 4 Belgian University Hos-
pitals: UZ-Ghent, UCL-Brussels, KUL-Leuven and ULg-Liege. Median donor
age was 35 years (range: 19-59). Majority of donors were children (57%) and
spouses (15%).
Results: Aborted procedures due to inaccurate preoperative volume assess-
ment were encountered in 7 (5%) donors. 136 donors actually underwent liver
donation. Complications occurred in 48/136 (35%), mostly due to UTI (14%),
biliary fistula (7%), nerve palsy (5.4%), pulmonary complications (5.4%), early
reoperation for bleeding and biliary complications (5.4%); and late reoperation
(cicatricial hernia’s) (3%). Portal vein thrombosis occurred in 3%. Mean hospi-
tal stay was 12±3 days. Hospital readmission was necessary in 3/135 (2.2%)
patients. One death occurred in a right lobe donor due to impaired remnant
liver regeneration and who expired after a sequential cascade of complications
and during urgent liver transplantation at postLTx day 49.
Conclusions: Incidence and type of donor complications after ALDLTx in Bel-
gium are comparable to those reported in the ELTR. Donor death is a rare
event (0.7%) related to impaired liver remnant regeneration. Inaccurate preop-
erative assessment also led to procedure abortion in 3%. This emphasizes the
need to more reliably predict preoperatively the actual liver volumes and the
regeneration capacity of the remnant liver.
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IL-33 stimulates the generation of cells, cytokine and immunoglobulin produc-
tion characteristic of a type 2 immune response. In this study, we demonstrate
the effect of IL-33 on allograft function during chronic cardiac rejection in mice.
B6: C-H2bm12/KhEg hearts were transplanted into wild type MHC class II-
mismatched C57BL/6J mice. IL-33 was administered i.p. daily. Cardiac allo-
grafts were harvested, graft infiltrating CD4+ T-cells were isolated and cytokine
production was determined by ELISA. Isolated leukocyte populations were ex-
amined by flow cytometry and alloantibody levels were determined. Further,
immunohistochemical staining of cardiac allografts was performed.
Allogeneic transplanted controls showed progressive allograft rejection within
21.5 days after transplantation, whereas allograft survival in IL-33-treated an-
imals was extended to more than 50 days. Prolonged allograft survival was
accompanied by significant changes in cytokine production by graft infiltrating
CD4+ T-cells. We observed a significant decrease in the production of proin-
flammatory IL-17A and significantly increased levels of Th2-cytokines IL-5, IL-
13 and antiinflammatory IL-10. In addition, IL-33 treatment resulted in home-
ostatic changes of the lymphoid and myeloid compartment in both the car-
diac allografts and periphery. Flow cytometric analyses demonstrated a reduc-
tion of graft-infiltrating CD19+b220+ B-cells following IL-33 therapy. Accord-
ingly, IL-33 treated mice showed reduced alloantibody levels in the serum and
less immunoglobulins as determined by immunohistochemical analysis of the
grafts. In addition, a significant decrease in graft infiltrating CD11bhigh Gr1high
granulocytes coinciding with a significant increase in suppressive CD11bhigh
Gr1intermediate myeloid cells was observed after IL-33 therapy.
IL-33 treatment prolongs allograft survival after cardiac transplantation in mice.
